Skip to main content
Equibles
AIM logo

AIM · AIM ImmunoTech Inc.

Track AIM — free

Use AIM with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about AIM

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.25 +0.01 (+6.26%)
Going-concern doubt — flagged Aug 7, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company has incurred losses from operations and operating cash outflows exceeded cash inflows from operating activities for the six months ended June 30, 2026. These conditions raise substantial doubt regarding the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements.”
View the 10-Q filed Aug 7, 2026
Market Cap
$7.12M
Shares
30.44M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.24 Open$0.24 Day$0.24–0.26 Since split$0.22–1.25 Avg vol 30d1.2M Short int914K · 3.0% float · 1.2d Short vol60% Last earningsJun 4, 2026 DataFeb 2026–Aug 2026 Filing10-Q · Aug 7

Raw chart and full-history price indicators begin at the captured split on Feb 10, 2026; bars on opposite sides are not compared.

The closing range begins at the captured split on Feb 10, 2026.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 7, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Very Weak Sentiment Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 14.9 · calm Equity put/call 0.52
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 50-day avg −20%
below
RSI (14) 42
neutral
MACD trend Positive
52-week position 2%
near low
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Very Weak
1-month return −5%
trailing
6-month return −76%
trailing
Relative strength −88%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+6% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.00% of float · ▼ -40.8% MoM · 1.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
19 holders — mid 3-yr range
Squeeze score 44
elevated · 0–100
Fundamentals
Weak
Revenue growth −48%
Y/Y
EPS growth +72%
Y/Y
Free cash flow $-11.0M
Balance sheet $1.5M
net debt
Quant / Vol
risk profile
Very High
Volatility 273%
annualized · 1-yr
Max drawdown −82%
past year
ATR 13.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 2 · 2
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−20% Bearish
RSI (14)
42 Neutral
MACD trend
Positive Bullish
52-week position
2% Bearish
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+6% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.00% of float · ▼ -40.8% MoM · 1.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
19 holders — mid 3-yr range
Price context
position in its range since split · 2026-02-10
Range low $0 Now $0 · 2% Range high $1
vs 50-day avg -20%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
AIM
AIM ImmunoTech Inc.
this stock
$7.12M — -48.2% — 3.0%
ONC
BeOne Medicines Ltd.
 $557.05B +24.0% +22179.2% 856.5 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $136.93B +21.8% +46.2% 31.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $86.39B +8.9% +20.8% 20.8 3.3%
MRNA
Moderna, Inc.
 $69.62B +491.3% +4.3% — 12.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
19
% held
3.8%
Net QoQ
+971.6K sh
Top holder
JANE STREET GROUP, LLC
Held Float
View
Held by Funds
Fund positions
2
View
Short & Settlement
Short Interest Falling
Shares short
913.9K
Days to cover
1.2d
Change
-629.9K sh
View
Short Volume
Short vol %
60%
As of
Aug 20, 2026
Short Total
View
Fails to Deliver
FTD shares
21.3K
Value
$5.1K
As of
Jul 31, 2026
View
Off-Exchange
Off-exchange %
70.6%
Week of
Jul 13, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$88.0K
Net income (FY)
$-14.0M
EPS diluted
$-8.62
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 11, 2026
This year
23
View
Exempt Offerings
Offering
$3.3M
Filed
Feb 21, 2024
View
Earnings & Events
Earnings Calls
Last call
Jun 4, 2026
View

Performance

Raw-price comparisons begin at the captured split on Feb 10, 2026; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
AIM -7.3% -4.7% -75.9% -4.7% —
SPY -0.4% +2.9% +11.6% +3.0% +12.8%
vs SPY -6.9% -7.6% -87.5% -7.7% —
Key facts CIK 946644 CUSIP 00901B303 13F (30d) 18 filings 18 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)